Skip to main content
SpringerLink
Log in

Cisplatin nephrotoxicity

A review

  • Review
  • Cisplatin Nephrotoxicity
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abe R, Akiyoshi T, Tsuji H, Baba T (1986) Protection of antiproliferative effect ofcis-diamminedichloroplatinum(II) by sodium thiosulfate. Cancer Chemother Pharmacol 18:98–100

    Google Scholar 

  2. Aggerwal SK, Whitehouse MW, Ramachandran C (1980) Ultrastructural effects of cisplatin. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: current status and new developments. Academic, New York, pp 79–111

    Google Scholar 

  3. Bell DR, Woods RL, Levi JA (1985)cis-Diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting. Eur J Cancer Clin Oncol 21:287–290

    Google Scholar 

  4. Bernard A, Buchet JP, Rock H, Masson P, Lauwerys R (1979) Renal excretion of proteins and enzymes in workers exposed to cadmium. Eur J Clin Invest 9:11–22

    Google Scholar 

  5. Bird JE, Walse MM, Queblemann AJ (1984) Protective effect of organic cation transport inhibitors oncis-diamminedichloroplatinum induced nephrotoxicity. J Pharmacol Exp Ther 231:752–758

    Google Scholar 

  6. Bitran JP, Desser RK, Billings AA, Kozloff MF, Shapiro CM (1982) Acute nephrotoxicity followingcis-dichlorodiammineplatinum. Cancer 49:1784–1788

    Google Scholar 

  7. Brenner BM, Baylis C, Deen WM (1976) Transport of molecules across renal glomerular capillaries. Physiol Rev 56: 502–534

    Google Scholar 

  8. Bridges CR, Myers BD, Brenner BM, Deen WM (1982) Glomerular charge alterations in human minimal change nephropathy. Kidney Int 22:677–684

    Google Scholar 

  9. Buamah PK, Howell A, Whitby H, Harpur ES, Gescher A (1982) Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. Cancer Chemother Pharmacol 8:281–284

    Google Scholar 

  10. Bucley JE, Clark UL, Meyer T, Pearlman NW (1984) Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 144:2347–2348

    Google Scholar 

  11. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, Trump BF (1982)cis-Diamminedichloroplatinum-induced acute renal failure in the rat. Kidney Int 21:54–64

    Google Scholar 

  12. Clifton G, Pearce C, O'Neill W (1982) Early polyuria in the rat following single dosecis-dichloroammine platinum(II). J Lab Clin Med 100:659–670

    Google Scholar 

  13. Cohen AI, Harberg J, Citrin DL (1981) Measurement of urinary beta-2-microglobulin in the detection of cisplatin nephrotoxicity. Cancer Treat Rep 65:1083–1085

    Google Scholar 

  14. Daugaard G, Rørth M (1986) High-dose cisplatin and VP-16 with bleomycin in the management of advanced metastatic germ cell tumors. Eur J Cancer Clin Oncol 22:477–485

    Google Scholar 

  15. Daugaard G, Abildgaard U, Amtorp O (1985) Acute effect ofcis-diamminedichloroplatinum on renal blood flow and glomerular filtration rate in dogs. In: Bach PH, Lock EA (eds) Renal heterogeneity and target cell toxicity. Wiley, London, pp 401–404

    Google Scholar 

  16. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, Leyssac PP, Amtorp O, Dikhoff TG (1986) Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol 9:308–316

    Google Scholar 

  17. Daugaard G, Abildgaard U, Larsen S, Holstein-Rathlou N-H, Amtorp O, Olesen HP, Leyssac PP (1987) Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol 10:54–64

    Google Scholar 

  18. Daugaard G, Strandgaard S, Holstein-Rathlou N-H, Fredriksen PL, Svendsen UG, Munck O, Leyssac PP (1987) The renal handling of sodium and water is not affected by the standard dose cisplatin treatment for testicular cancer. Scand J Clin Lab Invest 47:455–459

    Google Scholar 

  19. Daugaard G, Holstein-Rathlou N-H, Leyssac PP (1988) Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. J Pharmacol Exp Ther 224: 1081–1085

    Google Scholar 

  20. Daugaard G, Rossing N, Rørth M (1988) Effects of high-dose cisplatin on glomerular function in the human kidney. Cancer Chemother Pharmacol 21:163–167

    Google Scholar 

  21. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, Bruunshuus I, Bucher D, Leyssac PP (1989) Renal tubular functions in patients treated with high-dose cisplatin. Clin Pharmacol Ther (in press)

  22. deGislain C, Dumas M, d'Athis P, Lantissier JL, Escousse A, Guerrin J (1986) Urinary β-2-microglobulin: early indicator of high dosecis-diamminedichloroplatinum nephrotoxicity? Influence of furosemide. Cancer Chemother Pharmacol 18: 276–279

    Google Scholar 

  23. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH (1978) Long term effect ofcis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41: 1274–1281

    Google Scholar 

  24. Diener U, Knoll E, Ratge D (1982) Urinary excretion of alanine aminopeptidase andN-acetyl-β-d-glucosaminidase during sequential combination chemotherapy. J Clin Chem Clin Biochem 20:615–619

    Google Scholar 

  25. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner NW (1980) Mechanism of cisplatinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 7:551–556

    Google Scholar 

  26. Doolan CP, Alpen EL, Theil GB (1962) A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 32:65–79

    Google Scholar 

  27. Elmer M, Eskildsen PC, Kristensen Ø, Leyssac PP (1972) A comparison of renal function in rats anaesthetized with inactin and sodium amytal. Acta Physiol Scand 86:41–58

    Google Scholar 

  28. Favre HR, Wing AJ (1968) Simultaneous51Cr edetic acid, inulin and endogenous creatinine clearance in 20 patients with renal disease. Br Med J 1:84–86

    Google Scholar 

  29. Fjeldborg P, Sørensen J, Helkjær PE (1986) The long-term effect of cisplatin on renal function. Cancer 58:2214–2217

    Google Scholar 

  30. Foulkes EC, Blanck S (1982) Mechanism of inhibition of renal amino acid reabsorption in rabbits by heavy metals. Toxicol Appl Pharmacol 64:103–107

    Google Scholar 

  31. Garnett ES, Parsons V, Veall N (1967) Measurement of glomerular filtration rate in man using a51Cr/edetic-acid complex. Lancet I:818–819

    Google Scholar 

  32. Giebisch G, Windhager EE (1973) Electrolyte transport across renal tubular membranes. In: Orloff J, Berliner RW (eds) Handbook of physiology. Section 8, renal physiology. American Physiological Society, Washington, DC, p 315

    Google Scholar 

  33. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, sternberg SS (1977) The renal pathology in clinical trials ofcis-platinum(II)diamminedichloride. Cancer 39:1362–1371

    Google Scholar 

  34. Goren MP, Wright RK, Horowitz ME (1986) Cumulative renal damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 18:69–73

    Google Scholar 

  35. Goren MP, Forastiere AA, Wright RK, Horowitz ME, Dodge RK, Kamen BA, Viar MJ, Pratt CB (1987) Carboplatin (CBDCA), iproplatin (CHIP) and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol 19:57–60

    Google Scholar 

  36. Groth S, Nielsen H, Sørensen JB, Christensen JB, Pedersen AG, Rørth M (1986) Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17: 191–196

    Google Scholar 

  37. Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H (1983) Nephrotoxicity ofcis-diamminedichloroplatinum with or without ifosfamide in cancer treatment. Clin Physiol Biochem 1:17–26

    Google Scholar 

  38. Hayes DM, Cvitkovic E, Golber RB, Scheiner E, Helson L, Krakoff I (1977) High dosecis-platinumdiamminedichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381

    Google Scholar 

  39. Higby PJ, Wallace HJ, Holland JF (1975)cis-Diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 59:647–659

    Google Scholar 

  40. Hill JB, Russo A (1981) Cisplatin induced hypomagnesemic hypocalcemia. Arch Intern Med 141:1100

    Google Scholar 

  41. Hilton PJ, Lavender S, Roth Z, Jones NF (1969) Creatinine clearance in patients with proteinuria. Lancet II:1215–1216

    Google Scholar 

  42. Holstein-Rathlou N-H, Christensen P, Leyssac PP (1982) Effects of halothane-nitrous oxide inhalation anaesthesia and inactin on overall renal and tubular function in Sprague-Dawley and Wistar rats. Acta Physiol Scand 114: 193–201

    Google Scholar 

  43. Howell SB, Taetle R (1980) Effect of sodium thiosulfate oncis-dichlorodiammineplatinum(II) toxicity and anti-tumor activity in L1210 leukemia. Cancer Treat Rep 64:611–616

    Google Scholar 

  44. Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitonealcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43:1426–1431

    Google Scholar 

  45. Ishizawa M, Taniguchi S, Baba T (1981) Protection of sodium thiosulfate against lethal toxicity ofcis-diamminedichloroplatinum(II) in bacteria and mice. Jpn J Pharmacol 31: 883–889

    Google Scholar 

  46. Iwamoto Y, Kawano T, Uozumi J, Aoki K, Baba T (1984) “Two-route chemotherapy” using high-dose i.p. cisplatin and i.v. sodium thiosulfate antidote for peritoneally disseminated cancer in mice. Cancer Treat Rep 68:1367–1373

    Google Scholar 

  47. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Reidenberg MM (1980) Comparison of methods of evaluating nephrotoxicity of cisplatinum. Clin Pharmacol Ther 27:557–562

    Google Scholar 

  48. Khlar S, Tripathy K (1966) Evaluation of renal function in malnutrition. Arch Intern Med 118:322–325

    Google Scholar 

  49. Kovach JS, Moertel CG, Schutt AJ (1973) Phase II study ofcis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 57: 337–359

    Google Scholar 

  50. Krakoff IH (1979) Nephrotoxicity ofcis-dichlorodiammineplatinum(II). Cancer Treat Rep 63:1523–1525

    Google Scholar 

  51. Lammers PJ, White L, Ettinger LJ (1984) Cis-platinum induced renal sodium wasting. Med Pediatr Oncol 12:343–346

    Google Scholar 

  52. Lavender S, Hilton PJ, Jones NF (1969) The measurement of glomerular filtration rate in renal disease. Lancet II: 1216–1219

    Google Scholar 

  53. Legha SS, Dimery IW (1985) High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 3:1373–1378

    Google Scholar 

  54. Levi J, Jacobs C, Klman SM, McTigue M, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: I. Effect of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213: 545–550

    Google Scholar 

  55. Leyland-Jones B, Morrow C, Tate S, Urmacher C, Gordon C, Young W (1983)cis-Diamminedichloroplatinum(II) nephrotoxicity and its relationship to renal gamma-glutamyl transpeptidase and glutathione. Cancer Res 43:6072–6076

    Google Scholar 

  56. Litterst CL (1981) Alterations in the toxicity ofcis-dichlorodiammineplatinum(II) and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61:99–108

    Google Scholar 

  57. Madias NE, Harrington T (1978) Platinum nephrotoxicity. Am J Med 65:307–314

    Google Scholar 

  58. Markman M, Cleary S, Howell SB (1985) Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer Clin Oncol 21:1015–1018

    Google Scholar 

  59. Massry SG, Coburn JW, Chapman LW, Kleeman CR (1967) Effect of NaCl infusion on urinary calcium and magnesium during reduction in their filtered loads. Am J Physiol 213: 1218–1244

    Google Scholar 

  60. Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH (1985) Studies on the pathogenesis of cisplatin induced hypomagnesemia in rats. Kidney Int 28:914–921

    Google Scholar 

  61. McMurty RJ, Mitchell JR (1977) Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes including furosemide and cephaloridine Toxicol Appl Pharmacol 42:285–300

    Google Scholar 

  62. Meijer S, Sleifer DT, Mulder N, Sluiter WJ, Marrink J, Koops HS, Brouwers TM, Oldhoff J, Hems GK van der, Mandema E (1983) Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer 51:2035–2040

    Google Scholar 

  63. Miura K, Goldstein RS, Pasino DA, Hook JB (1987) Cisplatin nephrotoxicity: role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology 44: 147–158

    Google Scholar 

  64. Offerman JJG, Meijer S, Sleifer DTH, Mulder NH, Donker AJM, Schrafford Koops H, Hem GK van der (1984) Acute effects ofcis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 12:36–38

    Google Scholar 

  65. Ozols RF, Cordon BJ, Jacobs J, Wesley M, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24

    Google Scholar 

  66. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC (1988) A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6:1031–1040

    Google Scholar 

  67. Payne RB (1986) Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 23:243–250

    Google Scholar 

  68. Pera MF, Zook BC, Harder HC (1979) Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition ofcis-dichloroplatinum(II) in rats. Cancer Res 39: 1269–1278

    Google Scholar 

  69. Peterson PA, Evrin PE, Berggaard I (1969) Differentiation of glomerular, tubular and normal proteinuria: determination of urinary excretion of beta-2-microglobulin, albumin and total protein. J Clin Invest 48:1189–1198

    Google Scholar 

  70. Peterson PA, Berggaard I (1971) Urinary immunoglobulin components in normal, tubular and glomerular proteinuria: quantities and characteristics of free light chains, IgG, IgA and Fc-gamma fragments. Eur J Clin Invest 1:255–264

    Google Scholar 

  71. Pfeifle CE, Howell SB, Felthouse RD, Woliver TBS, Andrews PA, Markman M, Murphy MP (1985) High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 3:237–244

    Google Scholar 

  72. Phelps JS, Gandolfi AJ, Brendel K, Dorr RT (1987) Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices. Toxicol Appl Pharmacol 90:501–512

    Google Scholar 

  73. Portmans J, Bienenstock J (1975) Synthesis of immunoglobulins and 15 other proteins by diseased human kidneys. Eur J Clin Invest 5:365–371

    Google Scholar 

  74. Safirstein R, Miller P, Dikman S, Lyman S, Shapiro C (1982) Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 241:F175-F185

    Google Scholar 

  75. Safirstein R, Miller P, Guttenplan JR (1984) Uptake and metabolism of cisplatin by the kidney. Kidney Int 25:753–758

    Google Scholar 

  76. Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity: insights into mechanism. Int J Androl 10:325–346

    Google Scholar 

  77. Schaeppi V, Heyman IA, Fleischman RW (1973)cis-Diamminedichloroplatinum(II) (NSC-119875): preclinical toxicological evaluation of intravenous injection in dogs, monkeys and mice. Toxicol Appl Pharmacol 25:230–241

    Google Scholar 

  78. Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receivingcis-diamminedichloroplatinum(II). Ann Intern Med 90:929–931

    Google Scholar 

  79. Schilsky RL, Barlock A, Ozols RF (1980) Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 66:1767–1769

    Google Scholar 

  80. Schnermann I (1968) Micropuncture study of single short loops of Henle in rat kidney. Pflügers Arch 300:255–282

    Google Scholar 

  81. Shemesh O, Golbetz H, Kriss JP, Myers BD (1985) Limitations of creatinine as a filtration marker in glomerupathic patients. Kidney Int 28:830–838

    Google Scholar 

  82. Shils ME (1969) Experimental human magnesium depletion. Medicine 48:61–85

    Google Scholar 

  83. Slater JF, Almed M, Ibrahim SA (1977) Studies on the nephrotoxicity ofcis-dichlorodiammineplatinum and related substances. J Clin Hematol Oncol 7:534–544

    Google Scholar 

  84. Sørensen PG, Nissen MH, Groth S, Rørth M (1985) Beta-2-microglobulin excretion: an indicator of long term nephrotoxicity during cis-platinum treatment? Cancer Chemother Pharmacol 14:247–249

    Google Scholar 

  85. Stewart AF, Keating T, Schwartz RN, Schwartz PE (1985) Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol 153:660–665

    Google Scholar 

  86. Thomsen K (1984) Lithium clearance: A new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 37:217–223

    Google Scholar 

  87. Uozumi J, Litterst CL (1985) The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother Pharmacol 15:93–96

    Google Scholar 

  88. Uozumi J, Litterst CL (1986) The effect of sodium thiosulfate on subcellular localization of platinum in rat kidney after treatment with cisplatin. Cancer Lett 32:279–283

    Google Scholar 

  89. Uozumi J, Litterst L (1988) The effect of platinum levels in plasma, urine and kidney on blood urea nitrogen levels after cisplatin injection in rats. J Pharmacobiol Dyn 11:277–283

    Google Scholar 

  90. Uozumi J, Ishizawa M, Iwamoto Y, Baba T (1984) Sodium thiosulfate inhibitscis-diamminedichloroplatinum(II) activity. Cancer Chemother Pharmacol 13:82–85

    Google Scholar 

  91. Vogelzang NJ, Thorkelson JL, Kennedy BJ (1985) Hypomagnesemia, renal dysfunction and Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Cancer 56:2765–2770

    Google Scholar 

  92. Ward JN, Fauvie KA (1976) The nephrotoxic effect ofcis-diamminedichloroplatinum(II) (NSC-119875) in male F 344 rats. Toxicol Appl Pharmacol 38:535–547

    Google Scholar 

  93. Winston JA, Safirstein R (1985) Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490-F496

    Google Scholar 

  94. Wong NLM, Quamme GA, Sutton RAL, Dirks JH (1979) Effect of mannitol on water and electrolyte transport in the dog kidney. J Clin Lab Med 94:563–592

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology ONB, Rigshospitalet, Wiedeweltsgade 31, DK-2100, Copenhagen, Denmark

    Gedske Daugaard

  2. Department of Internal Medicine F, Herlev Hospital, Copenhagen, Denmark

    Ulrik Abildgaard

Authors
  1. Gedske Daugaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrik Abildgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Daugaard, G., Abildgaard, U. Cisplatin nephrotoxicity. Cancer Chemother. Pharmacol. 25, 1–9 (1989). https://doi.org/10.1007/BF00694330

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00694330

Keywords

Search

Navigation